Price$98.10+0.45 (+0.46%)
02:00 PM07:45 PM
News · 26 weeks71-20%
2026-04-192026-10-11
Mix3890d
- Insider26(68%)
- SEC Filings4(11%)
- Other4(11%)
- Earnings2(5%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for inte
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsMENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response®, a tissue-free, methylation-based liquid biopsy assay utilizing patented single-molecule counting technology to measure the absolute number of circulating tumor DNA (ctDNA) molecules, with a commercially available tumor-informed ctDNA assay for advanced cancer patients undergoing treatment. The study found that Northstar Response tracked disease dynamics on par with or better
- INSIDERChairman and CEO Atay Oguzhan exercised 8,333 shares at a strike of $2.80 and sold $1,326,919 worth of shares (10,999 units at $120.64) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 3,333 shares at a strike of $2.80 and sold $416,625 worth of shares (3,333 units at $125.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $169,920 worth of shares (1,416 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 22,219 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $150,960 worth of shares (1,416 units at $106.61) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 23,635 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Lynch Thomas P. exercised 35,112 shares at a strike of $13.61 and sold $3,873,966 worth of shares (35,112 units at $110.33) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 144 filed by BillionToOne Inc.144 - BillionToOne, Inc. (0002070849) (Subject)
- INSIDERChairman and CEO Atay Oguzhan exercised 24,999 shares at a strike of $2.80 and sold $3,030,444 worth of shares (30,331 units at $99.91) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Product Officer Sakakibara Shan Riku gifted 3,500 shares, decreasing direct ownership by 2% to 196,500 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $138,117 worth of shares (1,416 units at $97.54) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 25,051 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David sold $1,975,400 worth of shares (20,000 units at $98.77) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $2.80 (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Lynch Thomas P. exercised 20,000 shares at a strike of $13.61 and sold $1,999,880 worth of shares (20,000 units at $99.99) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan converted options into 20,000 shares and gifted 20,000 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David converted options into 20,000 shares and gifted 20,000 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 144 filed by BillionToOne Inc.144 - BillionToOne, Inc. (0002070849) (Subject)
- PRBillionToOne to Participate in the Wells Fargo 21st Annual Healthcare ConferenceMENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference. Management will participate in a fireside chat from 2:15pm to 2:50pm Eastern Time on Wednesday, September 9, 2026.A live and archived webcast will be available on the "Events & Presentations" page of BillionToOne's investor relations website at https://investors.billiontoone.com/news-events/events-presentation
- ANALYSTCanaccord Genuity initiated coverage on BillionToOne with a new price targetCanaccord Genuity initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00
- PRBillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of OriginNew add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genesMENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals. Northstar Origin is a physician-ordered add-on test to N
- INSIDERDirector Kolluri Krishna Kittu disposed of 484,442 shares and acquired 78,244 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
BLLN FAQ
6 questionsWhere does BLLN stock trade?
BillionToOne Inc. (BLLN) is listed on NASDAQ.What sector and industry is BLLN in?
BillionToOne Inc. operates in the Health Care sector, Medical Specialities industry.When did BillionToOne Inc. go public?
BillionToOne Inc. (BLLN) completed its IPO in 2025.What are analysts saying about BLLN?
BillionToOne Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-09-02.What companies are similar to BLLN?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare BLLN side-by-side with any of them on Quantisnow.How can I track BLLN on Quantisnow?
Quantisnow aggregates BillionToOne Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLLN to receive live email and push alerts on every new disclosure.